Samsung Biologics Co.,Ltd.
207940.KS
Get informed when a big investor buys or sells
+ FollowMarket Cap$56.43T
Close$
$1576204.06
31.2% upside
Current Fair Value
31.2% upsideUndervalued by 31.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $56.43 Trillion |
|---|---|
| Enterprise Value | $58.95 Trillion |
| Dividend Yield | $- (-) |
| Earnings per Share | $38588 |
| Beta | 0.19 |
| Outstanding Shares | 46,291,000 |
Return
| Return on Equity | 23.73% |
|---|---|
| Return on Assets | 15.68% |
| Return on Invested Capital | 25.35% |
Valuation & Multiples
| P/E Ratio | 28.42 |
|---|---|
| PEG | 86.72 |
| Price to Sales | 12.23 |
| Price to Book Ratio | 6.65 |
| Enterprise Value to Revenue | 12.97 |
| Enterprise Value to EBIT | 24.01 |
| Enterprise Value to Net Income | 29 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.34 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 23, 2026
EPS Estimate
$9356.32
Average shareholder expectationRevenue Estimate
$1319.83 B
Average shareholder expectationNext Earnings Call
Expected Date
October 27, 2026
EPS Estimate
$9799.29
Average shareholder expectationRevenue Estimate
$1356.32 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Samsung Biologics Co.,Ltd.
5,455 employees
CEO: John Chongbo Rim Samsung Biologics Co.,Ltd., established in 2011 and headquartered in Incheon, South Korea, provides contract services for biopharmaceutical products. The company's operations are divided into two main segments: Contract Manufacturing Org...